Alligator Bioscience AB stock analysis
Alligator Bioscience AB (0RK9) Share Price & Analysis
0RK9 Stock Chart & Stats
- Day’s Range
- SEK 0.01 - SEK 0.01
- 52-Week Range
- SEK 0.01 - SEK 0.34
- Previous Close
- SEK 0.01
- Volume
- N/A
- Average Volume (3M)
- 86.13K
- Market Cap
- SEK 28.54M
- Enterprise Value
- -SEK 907.86K
- Total Cash (Recent Filing)
- SEK 41.25M
- Total Debt (Recent Filing)
- SEK 27.78M
- Price to Earnings (P/E)
- ―
- Beta
- 0.46
- Next Earnings
- Feb 11, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Cancer Immunotherapy Specialization
A focused antibody-immunotherapy platform gives Alligator a defined scientific direction and the opportunity to build value across multiple development programs. Progress from research through clinical trials can create durable partnering opportunities if candidates demonstrate meaningful therapeutic potential.
Partnering-based Commercial Model
The intended out-licensing model can provide access to larger partners' development resources while preserving potential milestone and royalty participation. This approach may support commercialization without requiring Alligator to build a full sales infrastructure, although success depends on candidate progress and partner interest.
Reduced Losses Versus Prior Years
Smaller trailing losses than those recorded in 2023–2024 suggest some improvement in the scale of annual deterioration or operating costs. If maintained, this could extend financial runway and improve the company's ability to prioritize its pipeline, though losses remain substantial.
Bears Say
Deep And Continuing Unprofitability
The very small revenue base relative to the net loss shows that the company remains far from commercial breakeven. Continued development spending without meaningful product revenue leaves profitability dependent on future pipeline progress, licensing transactions, or additional financing.
Persistent Cash Burn
Recurring negative operating and free cash flow means research and clinical activity is consuming rather than generating cash. This reduces internal funding capacity and makes continued pipeline execution increasingly reliant on successful partnering, capital raising, or other financing.
High Leverage And Weak Equity Cushion
High debt relative to the equity base limits financial flexibility while operating losses continue. A volatile or negative equity position provides little cushion against further deterioration, potentially constraining investment in the pipeline and increasing dependence on external funding.
Alligator Bioscience AB News
0RK9 FAQ
What was Alligator Bioscience AB’s price range in the past 12 months?
What is Alligator Bioscience AB’s market cap?
When is Alligator Bioscience AB’s upcoming earnings report date?
How were Alligator Bioscience AB’s earnings last quarter?
Is Alligator Bioscience AB overvalued?
Does Alligator Bioscience AB pay dividends?
What is Alligator Bioscience AB’s EPS estimate?
How many shares outstanding does Alligator Bioscience AB have?
What happened to Alligator Bioscience AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Alligator Bioscience AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Alligator Bioscience AB
Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its drug development. These include ALLIGATOR-GOLD and ALLIGATOR-FAB, an extensive human antibody library boasting roughly 60 billion distinct antibody fragments; FIND, a molecular evolution technique used for optimizing antibodies and other proteins; and RUBY, a specialized format for creating bispecific antibodies. Alligator Bioscience's pipeline features several promising candidates. In the clinical stage, Mitazalimab, an immunostimulatory CD40 antibody, has successfully completed Phase I trials for metastatic cancer. Also undergoing Phase I clinical evaluation is ATOR-1017, another immunostimulatory antibody designed to bind to the 4-1BB receptor on tumor-specific T cells. For its preclinical efforts, the company is advancing ALG.APV-527, a bispecific antibody targeting both 4-1BB and 5T4 for cancer therapy. Additionally, Alligator Bioscience holds an interest in the Biosynergy (AC101) project, which is currently in Phase I. To bolster its research and development capabilities, Alligator Bioscience has formed multiple strategic collaborations. It has a co-development partnership with Aptevo Therapeutics Inc. for ALG.APV-527, and a research alliance with MacroGenics, Inc. to create novel immunotherapies. Further collaborations include a joint research agreement with BioArctic AB (publ) to utilize proprietary antibody generation technologies for new product candidates, and a research and license agreement with Orion Corporation aimed at discovering and developing new bispecific antibody cancer therapeutics. The company was established in 2000.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Søren Bregenholt
- Employees
- 11
- Website
- alligatorbioscience.se/en
- Address
- Medicon Village, Lund, SN, 223 81, SE
Alligator Bioscience AB (0RK9) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 4 | 14 |
| Technical Analysis | 3 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |






